Hong Kong
· Delayed Price · Currency is HKD InnoCare Pharma Statistics
Total Valuation
InnoCare Pharma has a market cap or net worth of HKD 13.89 billion. The enterprise value is 8.05 billion.
| Market Cap | 13.89B |
| Enterprise Value | 8.05B |
Important Dates
The last earnings date was Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoCare Pharma has 1.76 billion shares outstanding. The number of shares has increased by 0.57% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.76B |
| Shares Change (YoY) | +0.57% |
| Shares Change (QoQ) | +26.66% |
| Owned by Insiders (%) | 23.10% |
| Owned by Institutions (%) | 23.50% |
| Float | 1.06B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.78 |
| PB Ratio | 1.72 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -19.37 |
| EV / Sales | 8.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.35 |
Financial Position
The company has a current ratio of 7.74, with a Debt / Equity ratio of 0.23.
| Current Ratio | 7.74 |
| Quick Ratio | 7.03 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.20 |
| Interest Coverage | -24.69 |
Financial Efficiency
Return on equity (ROE) is -5.52% and return on invested capital (ROIC) is -4.84%.
| Return on Equity (ROE) | -5.52% |
| Return on Assets (ROA) | -4.00% |
| Return on Capital (ROIC) | -4.84% |
| Revenue Per Employee | 897,811 |
| Profits Per Employee | -375,042 |
| Employee Count | 1,089 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 1.19 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +0.73% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +0.73% |
| 50-Day Moving Average | 6.36 |
| 200-Day Moving Average | 5.20 |
| Relative Strength Index (RSI) | 52.43 |
| Average Volume (20 Days) | 5,428,459 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCare Pharma had revenue of HKD 995.67 million and -415.92 million in losses. Loss per share was -0.24.
| Revenue | 995.67M |
| Gross Profit | 856.57M |
| Operating Income | -690.82M |
| Pretax Income | -432.20M |
| Net Income | -415.92M |
| EBITDA | -610.39M |
| EBIT | -690.82M |
| Loss Per Share | -0.24 |
Balance Sheet
The company has 7.58 billion in cash and 1.71 billion in debt, giving a net cash position of 5.86 billion or 3.33 per share.
| Cash & Cash Equivalents | 7.58B |
| Total Debt | 1.71B |
| Net Cash | 5.86B |
| Net Cash Per Share | 3.33 |
| Equity (Book Value) | 7.56B |
| Book Value Per Share | 3.98 |
| Working Capital | 7.59B |
Cash Flow
In the last 12 months, operating cash flow was -611.94 million and capital expenditures -165.91 million, giving a free cash flow of -777.85 million.
| Operating Cash Flow | -611.94M |
| Capital Expenditures | -165.91M |
| Free Cash Flow | -777.85M |
| FCF Per Share | -0.44 |
Margins
Gross margin is 86.03%, with operating and profit margins of -69.38% and -41.77%.
| Gross Margin | 86.03% |
| Operating Margin | -69.38% |
| Pretax Margin | -43.41% |
| Profit Margin | -41.77% |
| EBITDA Margin | -61.30% |
| EBIT Margin | -69.38% |
| FCF Margin | -78.12% |
Dividends & Yields
InnoCare Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.57% |
| Shareholder Yield | -0.57% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |